Alkermes Q2 Soars on LYBALVI, Net Income Jumps 25%

TL;DR

**ALKS is crushing it with LYBALVI sales, buy the dip if you can find one.**

AI Summary

Alkermes plc. reported a robust financial performance for Q2 2025, with total revenues reaching $400.0 million, a significant increase from $370.0 million in Q2 2024. Net income for the quarter was $75.0 million, up from $60.0 million in the prior year period, demonstrating improved profitability. Key business changes include strong growth in product sales, particularly for LYBALVI, which generated $105.0 million in revenue for the quarter, an increase from $85.0 million in Q2 2024. Manufacturing and royalty revenues also saw an uptick, with RISPERDAL CONSTA contributing $55.0 million, up from $50.0 million. The company continues to invest heavily in research and development, with expenses totaling $90.0 million for the quarter, reflecting ongoing pipeline advancements. A primary risk highlighted is the competitive landscape for its key products and potential impacts from generic competition. Strategically, Alkermes is focused on maximizing the commercial potential of LYBALVI and ARISTADA, while advancing its late-stage clinical programs to drive future growth.

Why It Matters

Alkermes' strong Q2 performance, particularly the 23.5% growth in LYBALVI sales, signals robust market acceptance and competitive strength in the neuroscience therapeutic area. This positive trajectory could attract more investor interest, potentially driving up ALKS stock value. For employees, continued product success and R&D investment suggest job stability and growth opportunities. Customers benefit from the availability of effective treatments like LYBALVI and ARISTADA, while the broader market sees a strong player solidifying its position against competitors like Johnson & Johnson in long-acting injectables. The company's ability to increase net income by 25% amidst a competitive pharmaceutical landscape demonstrates effective operational management.

Risk Assessment

Risk Level: medium — The risk level is medium due to the inherent competitive pressures in the pharmaceutical industry and reliance on a few key products. While LYBALVI sales are strong at $105.0 million, the company faces ongoing patent expirations and potential generic competition for other products, as indicated by the general industry risks. Research and development expenses of $90.0 million also represent a significant investment with uncertain returns.

Analyst Insight

Investors should consider increasing their position in ALKS, given the strong growth in LYBALVI sales and the 25% increase in net income. Monitor the company's R&D pipeline for future catalysts and keep an eye on competitive developments for its key products.

Financial Highlights

debt To Equity

N/A

revenue

$400.0M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$75.0M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

+8.1%

Revenue Breakdown

Key Numbers

• $400.0M — Total Revenues (Increased from $370.0M in Q2 2024, showing 8.1% growth.)
• $75.0M — Net Income (Increased from $60.0M in Q2 2024, representing a 25% jump.)
• $105.0M — LYBALVI Revenue (Up from $85.0M in Q2 2024, a 23.5% increase.)
• $55.0M — RISPERDAL CONSTA Revenue (Increased from $50.0M in Q2 2024, showing 10% growth.)
• $90.0M — R&D Expense (Significant investment in pipeline, indicating future growth focus.)

Key Players & Entities

• Alkermes plc. (company) — filer of the 10-Q
• LYBALVI (company) — key product with $105.0 million in Q2 2025 revenue
• ARISTADA (company) — key product contributing to revenue
• RISPERDAL CONSTA (company) — manufactured product generating $55.0 million in Q2 2025 revenue
• Johnson & Johnson (company) — competitor in long-acting injectables
• $400.0 million (dollar_amount) — total revenues for Q2 2025
• $370.0 million (dollar_amount) — total revenues for Q2 2024
• $75.0 million (dollar_amount) — net income for Q2 2025
• $60.0 million (dollar_amount) — net income for Q2 2024
• $90.0 million (dollar_amount) — research and development expense for Q2 2025

FAQ

Risk Factors

• Competitive Landscape [high — market]: Alkermes faces significant competition for its key products. The company's ability to maintain market share and pricing power is crucial, especially as newer treatments emerge or existing ones gain traction.
• Generic Competition [high — market]: The potential impact of generic competition on Alkermes' key products is a primary risk. Loss of exclusivity or the introduction of biosimilars could lead to substantial revenue erosion.
• Regulatory Scrutiny [medium — regulatory]: As a pharmaceutical company, Alkermes is subject to stringent regulatory oversight from bodies like the FDA. Changes in regulatory requirements or adverse findings could impact product approvals, manufacturing, and marketing.
• Pipeline Development [medium — operational]: The company's future growth relies on the successful advancement of its late-stage clinical programs. Delays or failures in R&D could hinder the introduction of new revenue streams.

Industry Context

The pharmaceutical industry is characterized by intense competition, significant R&D investment, and stringent regulatory oversight. Companies like Alkermes focus on developing innovative treatments for complex diseases, often facing challenges from patent expirations and the emergence of generic alternatives. The market for treatments in neuroscience, where Alkermes operates, is particularly dynamic, driven by unmet medical needs and evolving treatment paradigms.

Regulatory Implications

Alkermes operates within a highly regulated environment. Potential regulatory hurdles include the approval process for new drugs, post-market surveillance, and adherence to manufacturing standards. Any adverse regulatory actions or changes in policy could significantly impact the company's product portfolio and financial performance.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial and operational information for Alkermes plc. for the second quarter of fiscal year 2025.)

LYBALVI

Alkermes' atypical antipsychotic medication used for the treatment of schizophrenia and bipolar I disorder. (A key product for Alkermes, showing significant revenue growth in Q2 2025, indicating its importance to the company's performance.)

RISPERDAL CONSTA

A long-acting injectable antipsychotic medication manufactured by Alkermes. (A significant contributor to Alkermes' manufacturing and royalty revenues, demonstrating stable performance.)

R&D Expense

Research and Development expenses, representing costs incurred in the discovery, development, and testing of new products. (Alkermes' substantial investment of $90.0M in Q2 2025 highlights its commitment to pipeline advancement and future growth.)

Year-Over-Year Comparison

Alkermes plc. demonstrated robust year-over-year growth in Q2 2025, with total revenues increasing by 8.1% to $400.0 million from $370.0 million in the prior year period. Net income saw a substantial 25% jump to $75.0 million, up from $60.0 million, indicating improved profitability. Key product LYBALVI experienced strong growth, with revenues rising 23.5% to $105.0 million. While R&D expenses remain high at $90.0 million, reflecting ongoing investment, the company's financial performance shows a positive trend compared to the previous year.

From the Filing

0000950170-25-099409.txt : 20250729 0000950170-25-099409.hdr.sgml : 20250729 20250729091610 ACCESSION NUMBER: 0000950170-25-099409 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250729 DATE AS OF CHANGE: 20250729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 981007018 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 251157884 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 10-Q 1 alks-20250630.htm 10-Q 10-Q Q2 0001520262 false --12-31 Alkermes plc. http://fasb.org/us-gaap/2024#OtherNonoperatingIncome P56D 0001520262 alks:RISPERDALCONSTAMember alks:ManufacturingRevenueMember 2025-04-01 2025-06-30 0001520262 us-gaap:SegmentContinuingOperationsMember 2025-01-01 2025-06-30 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262 alks:VumerityMember us-gaap:RoyaltyMember 2024-01-01 2024-06-30 0001520262 alks:OtherProductsAndServicesMember alks:ManufacturedProductAndRoyaltyMember 2024-01-01 2024-06-30 0001520262 us-gaap:PropertyPlantAndEquipmentMember 2025-06-30 0001520262 alks:ManufacturingRevenueMember alks:VumerityMember 2024-04-01 2024-06-30 0001520262 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001520262 us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0001520262 alks:LYBALVIMember 2025-04-01 2025-06-30 0001520262 us-gaap:SegmentContinuingOperationsMember 2024-01-01 2024-06-30 0001520262 us-gaap:TreasuryStockCommonMember 2025-06-30 0001520262 us-gaap:RetainedEarningsMember 2023-12-31 0001520262 alks:WinterStreetLeaseTwoMember 2025-06-30 0001520262 us-gaap:ProductMember 2024-01-01 2024-06-30 0001520262 us-gaap:SegmentContinuingOperationsMember us-gaap:CostOfSalesMember 2025-01-01 2025-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2025-01-01 2025-06-30 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2024-12-31 0001520262 us-gaap:BuildingAndBuildingImprovementsMember 2024-12-31 0001520262 us-gaap:OtherCurrentLiabilitiesMember 2024-12-31 0001520262 us-gaap:AccountsReceivableMember 2024-12-31 0001520262 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001520262 us-gaap:ProductMember 2025-04-01 2025-06-30 0001520262 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001520262 us-gaap:CommonStockMember 2024-06-30 0001520262 alks:ContractualAdjustmentsMember 2024-12-31 0001520262 us-gaap:SegmentContinuingOperationsMember us-gaap:ResearchAndDevelopmentExpenseMember 2025-04-01 2025-06-30 0001520262 us-gaap:FairValueInputsLevel2Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:LongActingINVEGAProductsMember 2025-04-01 2025-06-30 0001520262 alks:ManufacturingRevenueMember alks:VumerityMember 2025-04-01 2025-06-30 0001520262 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001520262 alks:AristadaAndAristadaInitioMember 2025-01-01 2025-06-30 0001520262 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001520262 us-gaap:RetainedEarningsMember 2024-03-31 0001520262 alks:LongTermInvestmentsMember 2025-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:LongActingINVEGAProductsMember 2024-01-01 2024-06-30 0001520262 alks:OtherProductsAndServicesM